Table 3.
Antibiotic-free days for the intention-to-treat and per-protocol analyses
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
|---|---|---|---|---|---|---|---|---|
| Intention-to-treat analysis | ||||||||
| Biomarker-guided recommendation on antibiotics group (n=102) | 50 (49%) | 13 (13%) | 7 (7%) | 10 (10%) | 7 (7%) | 3 (3%) | 4 (4%) | 8 (8%) |
| Routine use of antibiotics group (n=105) | 40 (38%) | 14 (13%) | 13 (12%) | 18 (17%) | 6 (6%) | 4 (4%) | 4 (4%) | 6 (6%) |
| Per-protocol analysis | ||||||||
| Biomarker-guided recommendation on antibiotics group (n=80) | 42 (53%) | 10 (13%) | 7 (9%) | 5 (6%) | 6 (8%) | 1 (1%) | 3 (4%) | 6 (8%) |
| Routine use of antibiotics group (n=105) | 40 (38%) | 14 (13%) | 13 (12%) | 18 (17%) | 6 (6%) | 4 (4%) | 4 (4%) | 6 (6%) |
Data are n (%).